|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/519 | (2006.01) |
| A61K 31/519 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| C12N 9/99 | (2006.01) | ||
| C12N 9/99 | (2013.01) |
| (11) | Number of the document | 3677266 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18851555.5 |
| Date of filing the European patent application | 2018-08-31 | |
| (97) | Date of publication of the European application | 2020-07-08 |
| (45) | Date of publication and mention of the grant of the patent | 2024-01-17 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/JP2018/032314 |
| Date | 2018-08-31 |
| (87) | Number | WO 2019/045036 |
| Date | 2019-03-07 |
| (30) | Number | Date | Country code |
| 2017168606 | 2017-09-01 | JP |
| (72) |
ABE, Naomi , JP
HASAKO, Shinichi , JP
|
| (73) |
Taiho Pharmaceutical Co., Ltd. ,
1-27, Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444,
JP
|
| (54) | EXON 18 AND/OR EXON 21 MUTANT EGFR SELECTIVE INHIBITOR |
| EXON 18 AND/OR EXON 21 MUTANT EGFR SELECTIVE INHIBITOR |